Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
about
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsThe role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityTargeting the tumor vasculature to enhance T cell activityImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunityTherapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.SimB16: modeling induced immune system response against B16-melanoma4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapySimulating cancer growth with multiscale agent-based modelingIntermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunityHIF transcription factors, inflammation, and immunity.Agonist antibodies to TNFR molecules that costimulate T and NK cellsFocusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotypeImmunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsEmerging therapeutic targets in metastatic progression: A focus on breast cancer.Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanomaAdvances in targeting cell surface signalling molecules for immune modulationEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.Control of the adaptive immune response by tumor vasculature.Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Hypoxia and antitumor CD8+ T cells: An incompatible alliance?The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy.A mathematical model of immune-system-melanoma competitionDelivering safer immunotherapies for cancer.Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
P2860
Q26779221-7F9BB6BA-7A35-4910-9882-3D32DDCAF007Q26996707-47CFCDE5-1D97-43D6-AFD6-E2FD1A1F2DBDQ27012963-707C39E0-0C06-4131-BA59-A16B1FF6E028Q27026329-950227E3-A787-45FE-ACC1-604867D793CBQ27027633-4D0D7BBD-795C-42D8-A283-14C1E43048B6Q30299955-20C1EC53-30DB-469A-BAA4-C04B3BED20DCQ33426409-FB7E6E5E-171D-4CAA-A91D-FC6033E5A58BQ33887448-4EFE68A4-7BA5-409E-9397-1498A5FDD56CQ34058636-C143D573-4653-4267-9FBA-8560ADB7A380Q34180031-0F693559-5F06-4DFF-82B5-B311AE2C6D0EQ34438611-824000B9-0D82-4AE1-9069-21C867346BF7Q35051306-BC24E1BE-25EE-448D-8824-FB1965C39798Q35108680-9DF48C14-325A-4E4C-8DD1-EE8079F36B0CQ35137138-23CE1C46-9722-44F8-90AC-9EB62E226B12Q35427446-48C62A1E-8697-4C43-8DD6-2C3C485A0009Q35764479-0C416FE6-0A8E-49F3-9FB2-FC1E66AE3D57Q36204132-62E2FB1B-DD95-4E14-AF9A-9EB33A0891B7Q36220613-9DF22E63-15D4-41B0-8DE1-71695EA27A81Q36419956-0794A9CA-FEAA-4F8C-8C66-E75E2ED54520Q36449290-2254EF8D-B0C8-46CC-8B2C-82D9608E99D2Q36597479-DCD8A448-CA76-4496-A85A-4355EB6C778EQ36778827-195466B1-431C-4210-9662-669F0EFF0385Q36854062-A4E66471-CEAC-4F62-A6B6-D3C2C265CA74Q36936587-AC0CF7D7-1566-403A-B2EB-E10E4D1D70B0Q36973787-52B6D936-C6AA-424C-8752-B6DA1194F184Q37158481-5C785868-CE12-4ED0-AB94-0D5BD0D93447Q37222143-D23DDEDB-4A24-421D-B041-A5C357E7C79BQ37410596-7FD652E5-9EE2-4424-9BD9-DCE671BF110BQ37683575-1D6FCBE8-A8CC-4031-BA9C-36D7BB7F5A77Q37939726-65E3F24A-E8DF-4DE3-8EC0-F9DC8B3A3550Q37948129-1A4431BC-2296-49C3-9C23-2DBC0AAAD426Q38081999-68B8EFEC-1439-4660-9AFD-03FEB3E7DC5EQ38698632-11B0C35E-C169-4716-A3C6-C0E9556A31B4Q38998450-58E12CF3-840A-4040-875D-2C8FE7C378B1Q39155959-BC20C91F-A54A-4597-833D-1BC0580642F7Q39330809-ECA60D59-2C80-490C-A870-47991C6FEC99Q39330984-52B937D0-D6B0-4C4C-AEE4-48DE67A98E0AQ39381907-ED1FF0FD-ED86-415E-A193-00F492B44530Q39406918-998E0FC7-C68A-4227-9904-FB1399FA34E6Q39575747-BFB78381-3377-4065-9065-065A12D39FF2
P2860
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@en
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@nl
type
label
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@en
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@nl
prefLabel
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@en
Agonist anti-CD137 mAb act on ...... nt of activated T lymphocytes.
@nl
P2093
P50
P1433
P1476
Agonist anti-CD137 mAb act on ...... ent of activated T lymphocytes
@en
P2093
Aizea Morales-Kastresana
Alfonso Luque
Ana Rouzaut
Ignacio Melero
Iván Martínez-Forero
Joseph Dinchuk
Juan Dubrot
Maria Jure-Kunkel
P304
P356
10.1158/0008-5472.CAN-10-1733
P407
P50
P577
2011-01-25T00:00:00Z